0VGI Stock Overview A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
TG Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for TG Therapeutics Historical stock prices Current Share Price US$31.97 52 Week High US$37.15 52 Week Low US$12.91 Beta 2.24 1 Month Change 3.85% 3 Month Change 19.96% 1 Year Change 93.52% 3 Year Change 216.85% 5 Year Change n/a Change since IPO 536.85%
Recent News & Updates TG Therapeutics, Inc. Provides Revenue Guidance for Fourth Quarter, Full Year of 2024 and Full Year 2025 Jan 15
CFO, Corporate Secretary & Treasurer recently sold US$629k worth of stock Jan 10
Independent Director recently sold US$490k worth of stock Nov 08
Third quarter 2024 earnings released: EPS: US$0.027 (vs US$0.80 in 3Q 2023) Nov 04
TG Therapeutics, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Nov 01
TG Therapeutics, Inc. Announces Updated Data Presentations Including New Five-Year Data from ULTIMATE I & II Phase 3 Trials Evaluating BRIUMVI (Ublituximab-Xiiy) in Patients with Relapsing Forms of Multiple Sclerosis Sep 18 See more updates TG Therapeutics, Inc. Provides Revenue Guidance for Fourth Quarter, Full Year of 2024 and Full Year 2025 Jan 15
CFO, Corporate Secretary & Treasurer recently sold US$629k worth of stock Jan 10
Independent Director recently sold US$490k worth of stock Nov 08
Third quarter 2024 earnings released: EPS: US$0.027 (vs US$0.80 in 3Q 2023) Nov 04
TG Therapeutics, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Nov 01
TG Therapeutics, Inc. Announces Updated Data Presentations Including New Five-Year Data from ULTIMATE I & II Phase 3 Trials Evaluating BRIUMVI (Ublituximab-Xiiy) in Patients with Relapsing Forms of Multiple Sclerosis Sep 18
Investor sentiment improves as stock rises 16% Aug 19
TG Therapeutics Receives U.S. Food and Drug Administration Clearance for Its Investigational New Drug (IND) Application Aug 09
New major risk - Share price stability Aug 08
Second quarter 2024 earnings released: EPS: US$0.048 (vs US$0.34 loss in 2Q 2023) Aug 07
TG Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Aug 05
Investor sentiment improves as stock rises 15% Jul 13
Investor sentiment improves as stock rises 15% Jun 26
Independent Director recently sold US$433k worth of stock Jun 21
Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission Jun 14
CalSTRS Files an Exempt Solicitation Statement to Shareholders of TG Therapeutics Jun 13
New minor risk - Shareholder dilution May 08
Investor sentiment improves as stock rises 26% May 08
First quarter 2024 earnings released: US$0.073 loss per share (vs US$0.28 loss in 1Q 2023) May 01 TG Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024
Lead Independent Director recently sold US$351k worth of stock Mar 14
Full year 2023 earnings released: EPS: US$0.089 (vs US$1.47 loss in FY 2022) Feb 29
TG Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 05
Forecast breakeven date pushed back to 2025 Jan 11
CFO, Corporate Secretary & Treasurer recently sold US$809k worth of stock Jan 06
Forecast breakeven date moved forward to 2024 Nov 02
Third quarter 2023 earnings released: EPS: US$0.80 (vs US$0.27 loss in 3Q 2022) Nov 02
TG Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 31
Forecast breakeven date pushed back to 2025 Oct 13
Chairman recently bought US$1.0m worth of stock Aug 15
Second quarter 2023 earnings released: US$0.34 loss per share (vs US$0.30 loss in 2Q 2022) Aug 02
TG Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Aug 01
Independent Director recently sold US$815k worth of stock Jun 27
Forecast breakeven date moved forward to 2024 Jun 26
CFO, Corporate Secretary & Treasurer recently sold US$2.0m worth of stock Jun 06
Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults Jun 03
Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults Jun 02
First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.51 loss in 1Q 2022) May 02
Insufficient new directors May 01
No longer forecast to breakeven Mar 03
Forecast to breakeven in 2025 Mar 01
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum Feb 15
TG Therapeutics Announces Commercial Launch of BRIUMVI™ (ublituximab-xiiy) for the Treatment of Adult Patients with Relapsing Forms of Multiple Sclerosis Jan 28
Lead Independent Director recently sold US$333k worth of stock Jan 08
Forecast to breakeven in 2025 Dec 31
TG Therapeutics, Inc. Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy) Dec 29
TG Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 09
Hagens Berman, National Trial Attorneys, Encourages TG Therapeutics Investors with Losses to Contact Firm’S Attorneys Before Sept. 16Th Deadline in Securities Fraud Class Action Sep 07
TG Therapeutics, Inc. Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Aug 26
Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.59 loss in 2Q 2021) Aug 08
Pomerantz Law Firm Announces the Filing of A Class Action Against TG Therapeutics, Inc Jul 19
TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS Jun 01
First quarter 2022 earnings released: US$0.51 loss per share (vs US$0.69 loss in 1Q 2021) May 11
TG Therapeutics, Inc., Annual General Meeting, Jun 16, 2022 May 02
TG Therapeutics, Inc. Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL Apr 16
TG Therapeutics, Inc. Announces Data Presentations from the Ultimate I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented At the American Academy of Neurology Annual Meeting Apr 05
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL Mar 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 02
TG Therapeutics, Inc. Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum Feb 26
TG Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022 Feb 25 TG Therapeutics, Inc. Announces Data from the UNITY-CLL Phase 3 Trial Presented At the 63rd American Society of Hematology Annual Meeting
Third quarter 2021 earnings released: US$0.65 loss per share (vs US$0.73 loss in 3Q 2020) Nov 06
TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances Sep 24
TG Therapeutics, Inc. Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia Sep 21
Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.47 loss in 2Q 2020) Aug 03
No longer forecast to breakeven Aug 03 TG Therapeutics, Inc.(NasdaqCM:TGTX) dropped from Russell 3000E Value Index
TG Therapeutics, Inc. Announces Presentation of Data from the Ultimate I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis At 7th Congress of the European Academy of Neurology Jun 19
TG Therapeutics, Inc. Announces Data from Phase 1 Study Evaluating TG-1701 as a Monotherapy Jun 05
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with UKONIQ® (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma May 26
First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.48 loss in 1Q 2020) May 11
New 90-day low: US$39.10 Mar 14
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2B Trial Evaluating Umbralisib Mar 10
TG Therapeutics, Inc. to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the American Academy of Neurology 73rd Annual Meeting Mar 05
Full year 2020 earnings released: US$2.42 loss per share (vs US$1.96 loss in FY 2019) Mar 02
Revenue misses expectations Mar 02
TG Therapeutics, Inc. to Report Q4, 2020 Results on Mar 02, 2021 Feb 27
TG Therapeutics Announces Publication of Final Results from the Phase 3 Genuine Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in the Lancet Haematology Feb 24
TG Therapeutics, Inc. Announces FDA Accelerated Approval of UKONIQ™ (Umbralisib) Feb 06
TG Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.92 million. Dec 15
Independent Director recently sold US$1.2m worth of stock Dec 12
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis Dec 12
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in Blood Dec 03
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Approval of Ublituximab Investigational Glycoengineered Anti-CD20 Monoclonal Antibody Dec 02
Revenue beats expectations Nov 11
Third quarter 2020 earnings released: US$0.73 loss per share Nov 11
First half earnings released Aug 15 Shareholder Returns 0VGI GB Biotechs GB Market 7D 5.3% 5.1% 2.0% 1Y 93.5% -17.6% 10.8%
See full shareholder returns
Return vs Industry: 0VGI exceeded the UK Biotechs industry which returned -17.6% over the past year.
Return vs Market: 0VGI exceeded the UK Market which returned 10.8% over the past year.
Price Volatility Is 0VGI's price volatile compared to industry and market? 0VGI volatility 0VGI Average Weekly Movement 9.6% Biotechs Industry Average Movement 9.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.8% 10% least volatile stocks in GB Market 2.7%
Stable Share Price: 0VGI's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0VGI's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
Show more TG Therapeutics, Inc. Fundamentals Summary How do TG Therapeutics's earnings and revenue compare to its market cap? 0VGI fundamental statistics Market cap US$4.55b Earnings (TTM ) -US$14.36m Revenue (TTM ) US$264.79m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0VGI income statement (TTM ) Revenue US$264.79m Cost of Revenue US$30.94m Gross Profit US$233.85m Other Expenses US$248.21m Earnings -US$14.36m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.10 Gross Margin 88.31% Net Profit Margin -5.42% Debt/Equity Ratio 127.1%
How did 0VGI perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/01 03:48 End of Day Share Price 2025/01/31 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources TG Therapeutics, Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alec Stranahan BofA Global Research Jonathan Aschoff Brean Capital Mayank Mamtani B. Riley Securities, Inc.
Show 17 more analysts 
